Hypersensitivity, Immediate Active Not Recruiting Phase 2 Trials for Tezepelumab (DB15090)

Also known as: Type I Hypersensitivity / Immediate Hypersensitivity / Hypersensitivity type I / Hypersensitivity type I NOS / Immediate hypersensitivity reaction

IndicationStatusPhase
DBCOND0031076 (Hypersensitivity, Immediate)Active Not Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03688074Study to Evaluate Tezepelumab on Airway Inflammation in Adults With Uncontrolled Asthma (CASCADE)Treatment